When Sanofi's Genzyme Corp. unit launches multiple sclerosis drug Aubagio teriflunomide this month, its job will be to overcome physician sentiment that the drug's pregnancy restrictions and modest efficacy will relegate it to second- or third-line use.

The company is banking on the safety and tolerability of Aubagio to give the oral drug a leg up over first-line injectables.